Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder

Zerrin Karaaslan; Vuslat Yilmaz; Hande Yuceer; Elif Sanli; Halil Ibrahim Akcay; Murat Kurtuncu; Recai Turkoglu; Erdem Tuzun

doi:10.14744/nci.2022.77861

Serum CXCL5 as a biomarker in multiple sclerosis and neuromyelitis optica spectrum disorder

North Clin Istanb. 2023 Jun 19;10(3):341-344. doi: 10.14744/nci.2022.77861. eCollection 2023.

Authors

Zerrin Karaaslan¹, Vuslat Yilmaz¹, Hande Yuceer¹, Elif Sanli¹, Halil Ibrahim Akcay², Murat Kurtuncu², Recai Turkoglu³, Erdem Tuzun¹

Affiliations

¹ Department of Neuroscience, Istanbul University, Aziz Sancar Institute of Experimental Medicine, Istanbul, Turkiye.
² Department of Neurology, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkiye.
³ Department of Neurology, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkiye.

Abstract

Objective: Our aim was to determine whether serum C-X-C motif chemokine 5 (CXCL5) may serve as a diagnostic biomarker for relapsing-remitting multiple sclerosis (RRMS) as well as a marker that can be used to predict treatment response.

Methods: CXCL5 levels were measured by ELISA in sera of 20 RRMS patients under fingolimod treatment, 10 neuromyelitis optica spectrum disorder (NMOSD) patients, 15 RRMS patients presenting predominantly with spinal cord and optic nerve attacks (MS-SCON), and 14 healthy controls.

Results: Fingolimod treatment significantly reduced CXCL5 levels. CXCL5 levels were comparable among NMOSD and MS-SCON patients.

Conclusion: Fingolimod might regulate the innate immune system. Serum CXCL5 measurement does not differentiate between RRMS and NMOSD.

Keywords: C-X-C motif chemokine 5; fingolimod; multiple sclerosis; neuromyelitis optica spectrum disorder.